When Alembic Chemical Works opened its doors in Vadodara in 1907, the Indian pharmaceutical industry did not yet exist. The company began by producing tinctures and alcohol, primitive by modern standards but foundational for a nation that would need to build its own drug-manufacturing capability from scratch. More than 115 years later, Alembic Pharmaceuticals is a $904 million company with 342 FDA approvals, 9 manufacturing plants, and R&D operations spanning three countries. Few companies anywhere in the world can trace an unbroken line from the pre-independence era to the front ranks of global generics competition.
Alembic’s story begins in 1907 in Vadodara, Gujarat, decades before Indian independence and long before the concept of a domestic pharmaceutical industry had taken shape. The company started as Alembic Chemical Works, producing tinctures, alcohol, and basic chemical preparations. It was, in the truest sense, a pioneer: one of the first Indian enterprises to attempt industrial-scale chemical manufacturing.
The pivotal moment came in 1961, when Prime Minister Lal Bahadur Shastri personally inaugurated Alembic’s penicillin manufacturing plant. At a time when India was overwhelmingly dependent on imported antibiotics, the ability to produce penicillin domestically was a matter of national significance. That plant represented something larger than a single product line. It was proof that Indian companies could manufacture complex pharmaceuticals to international standards.
From that foundation, Alembic evolved steadily across the following decades, expanding from bulk chemicals and APIs into finished-dosage formulations, building regulatory expertise, and eventually filing for approvals with the US FDA. The company that once produced tinctures in colonial-era Gujarat now operates 9 manufacturing plants and holds 342 FDA approvals, the 6th highest count among all Indian pharmaceutical companies.
With 340 approved ANDAs and 2 NDAs, Alembic ranks as the 6th largest Indian filer of abbreviated new drug applications with the US FDA. That number is not merely a regulatory statistic. Each ANDA represents a complete dossier demonstrating bioequivalence, manufacturing quality, and stability data sufficient to satisfy one of the world’s most demanding regulatory agencies. Building a portfolio of 342 approvals requires sustained investment in analytical chemistry, formulation science, and regulatory affairs over many years.
The US generics strategy at Alembic is built on volume and breadth. Rather than concentrating on a handful of high-value molecules, the company has filed across a wide range of therapeutic categories and dosage forms. This approach carries lower per-product margins than a niche strategy, but it provides resilience: when pricing pressure hits one molecule, the portfolio absorbs the impact. It also means Alembic maintains deep institutional knowledge of FDA filing requirements, inspection protocols, and post-approval compliance, capabilities that compound over time and are difficult for newer entrants to replicate.
The company’s R&D operations are spread across three locations: Vadodara and Hyderabad in India, and a facility in New Jersey, USA. This geographic distribution allows Alembic to maintain proximity to both the FDA and the manufacturing plants that will ultimately produce approved products.
Alembic operates 9 manufacturing plants, concentrated primarily in Gujarat with an additional formulation facility in Sikkim. The manufacturing footprint divides into two categories: 5 formulation plants and 3 dedicated API (active pharmaceutical ingredient) plants, plus the Sikkim facility. Eight of these facilities carry US FDA registration, a density of regulatory-grade manufacturing that few Indian companies can match.
The key API manufacturing sites are located at Panelav (Plants 1&2, API-I, API-II), Karkhadi (Plant 3, API-III), and Jarod (Plant 4). This vertical integration, producing both the active ingredients and the finished dosage forms, gives Alembic control over its supply chain that pure formulation companies lack. When supply disruptions hit the global API market, vertically integrated manufacturers have a structural advantage.
The concentration of facilities in Gujarat is not accidental. Vadodara has been Alembic’s home for over a century, and the surrounding region has developed a deep ecosystem of skilled pharmaceutical workers, chemical suppliers, and regulatory expertise. Building a new plant near existing operations allows Alembic to leverage shared infrastructure, experienced personnel, and established relationships with regulatory inspectors who are familiar with the company’s quality systems.
In 2025, Alembic acquired Utility Therapeutics Ltd, a UK-based pharmaceutical company, for $12 million. The acquisition signals a strategic expansion beyond the company’s traditional US and Indian markets into Europe, where regulatory and commercial dynamics differ substantially from the ANDA-driven US generics business. European markets reward companies that can navigate country-by-country pricing negotiations, tender processes, and decentralised regulatory procedures.
The UK acquisition sits alongside continued investment in R&D across the company’s three research centres in Vadodara, Hyderabad, and New Jersey. With revenue growing at 7% year-over-year to reach $904 million in FY25, Alembic is approaching the billion-dollar threshold, a milestone that would place it firmly among India’s largest pharmaceutical companies by revenue.
For a company that started producing tinctures in 1907, the trajectory from Alembic Chemical Works to a near-billion-dollar global generics company with 342 FDA approvals is a testament to sustained, patient investment in manufacturing quality and regulatory capability. The next chapter, European expansion, a growing ANDA portfolio, and continued vertical integration, builds on strengths that have been compounding for over a century.
Sources: Alembic Pharmaceuticals Limited Annual Reports FY2020–21 through FY2024–25. US FDA facility registration and drug approval data. Company investor presentations and corporate filings (BSE/NSE: APLLTD).